Cannabis
Participants will smoke a cannabis cigarette ad libitum as per their usual routine
MarijuanaLoading study record…
Loading study record…
This study was authorized by the California Legislature (Assembly Bill 266, the Medical Marijuana Regulation and Safety Act to help with detection of driving under the influence of cannabis. One hundred and eighty healthy volunteers will inhale smoked cannabis with either 0% (placebo), 5.9%, or 13.4% Δ9-tetrahydrocannabinol (THC) at the beginning of the day, and then complete driving simulations, iPad-based performance assessments, and bodily fluid draws (e.g., blood, saliva, breath) before the cannabis smoking and a number of times over the subsequent 6 hours after cannabis smoking. The purpose is to determine (1) the relationship of the dose of Δ9-THC on driving performance and (2) the duration of driving impairment in terms of hours from initial use, (3) if saliva or expired air can serve as a useful substitute for blood sampling of Δ9-THC, and (4) if testing using an iPad can serve as a useful adjunct to the standardized field sobriety test in identifying acute impairment from cannabis.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2022-01-04
What this record can show
Results are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
Registry facts
There are several studies that suggest higher doses of whole-blood Δ9-tetrahydrocannabinol (Δ9-THC) concentration are associated with increased crash risk and crash culpability. However, attempts to define a cut-off point for blood Δ9-THC levels have proven to be challenging. Unlike alcohol, for which a level can be reasonably measured using a breathalyzer (and confirmed with a blood test), detection of a cut-off point for intoxication related to Δ9-THC concentration has eluded scientific verification. Recent evidence suggests blood Δ9-THC concentrations of 2-5 ng/mL are associated with substantial driving impairment, particularly in occasional smokers. Others have countered that this level leads to false positives, particularly in heavy cannabis users inasmuch as THC may be detectable in their blood specimens for 12-24 hours after inhalation. Given that 12 to 24 hours is beyond the likely period of driving impairment, this would appear to be a justifiable objection to a per se cut-off point for a Δ9-THC concentration indicative of impairment. Maximal driving impairment is found 20 to 40 minutes after smoking, and the risk of driving impairment decreases over the following hours, at least in those who smoke 18 mg Δ9-THC or less, the dose often used experimentally to duplicate a single joint. Other studies, however, report residual motor vehicle accident crash risk when cannabis is used within 4 hours prior to driving. The roadside examination using the Standardized Field Sobriety Test (SFST) for proof of cannabis-related impairment has not been an ideal alternative to blood levels. Originally devised to evaluate impairment under the influence of alcohol, the SFST is comprised of three examinations administered in a standardized manner by law enforcement officers. The 'Horizontal Gaze Nystagmus' (HGN), the 'One Leg Stand' (OLS) and the 'Walk and Turn' test (WAT) require a person to follow instructions and perform motor activities. During the assessments, officers observe and record signs of impairment. In one study, Δ9-THC produced impairments on overall SFST performance in 50 % of the participants. In a separate study involving acute administration of cannabis, 30% of people failed the SFST. This discrepancy was thought to be in part due to the participant's cannabis use history, as well as low percentage of THC in the cannabis. The reported frequency of cannabis use varied from once a week to once every 2-6 months in the study where there was a failure on the SFST by 50% of the participants. The other study included more frequent users who smoked cannabis on at least four occasions per week. Based upon the above, another means is needed to help law enforcement officers discern driving under the influence of cannabis. One future possibility is the development of performance-based measures of cannabis-related impairments. This will include testing of critical tracking, time estimation, balance and visual spatial learning. The investigators have selected brief measures in order to be practicably administered repeatedly over a short time period, as well as tests that have the potential to translate to a field-feasible tablet-based format, should there be benefit in possibly including these in future performance-based measures for use in the field by law enforcement officers (e.g., a cannabis-focused field sobriety test).
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Research network
Interventions
Participants will smoke a cannabis cigarette ad libitum as per their usual routine
MarijuanaSource-reported results
Results are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
The Composite Drive Score (CDS) is a z-score comprised of key variables from the simulator tasks (SDLP, speed deviation, and task accuracy during the modified Surrogate Reference Task (mSuRT); coherence from the car following task). This outcome reflects the change in CDS from the pre-smoking assessment, at each timepoint. The z-score indicates the number of standard deviations away from the mean from the baseline performance for the entire group (n = 191). A Z-score of 0 is equal to the mean of a reference population (in this case the pre-smoking performance for the entire group). Higher z-scores at each timepoint indicate worse performance (variables that went in the opposite direction were reflected in order to have all variables have the same direction). When examining the change in Composite Drive Score (this outcome variable), a higher score indicates a decline in performance (e.g., Time 2 minus Time 1).
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | -.09 | .64 |
| 5.9% THC | 66 | .12 | .58 |
| 13.4% THC | 62 | .01 | .52 |
| Placebo | 63 | -.17 | .61 |
| 5.9% THC | 66 | .46 | .60 |
| 13.4% THC | 62 | .21 | .60 |
| Placebo | 63 | -.13 | .61 |
| 5.9% THC | 66 | .40 | .66 |
| 13.4% THC | 62 | .32 | .59 |
| Placebo | 63 | -.23 | .59 |
| 5.9% THC | 66 | .15 | .64 |
| 13.4% THC | 62 | .04 | .57 |
| Placebo | 63 | -.07 | .66 |
| 5.9% THC | 66 | .09 | .57 |
| 13.4% THC | 62 | .05 | .59 |
This measures the standard deviation of lateral (lane) position, or the degree to which the participant "swerves" within the road lane on the driving simulation during the modified Surrogate Reference Task (mSuRT). The range is from .39 to 3.33. A higher score indicates worse performance.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | 1.09 | .36 |
| 5.9% THC | 66 | 1.20 | .36 |
| 13.4% THC | 62 | 1.11 | 0.35 |
| Placebo | 63 | 1.07 | .33 |
| 5.9% THC | 66 | 1.24 | .36 |
| 13.4% THC | 62 | 1.19 | .36 |
| Placebo | 63 | 1.06 | .31 |
| 5.9% THC | 66 | 1.31 | .39 |
| 13.4% THC | 62 | 1.23 | .42 |
| Placebo | 63 | 1.10 | .31 |
| 5.9% THC | 66 | 1.25 | .35 |
| 13.4% THC | 62 | 1.20 | .42 |
| Placebo | 63 | 1.10 | .36 |
| 5.9% THC | 66 | 1.25 | .37 |
| 13.4% THC | 62 | 1.18 | .42 |
The variability in speed during the modified Surrogate Reference Test (mSuRT). The speed is in miles per hour. Range is from .17 to 12.85. A higher score indicates worse performance.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | 2.13 | 1.81 |
| 5.9% THC | 66 | 2.61 | 1.97 |
| 13.4% THC | 62 | 2.63 | 1.98 |
| Placebo | 63 | 2.03 | 1.31 |
| 5.9% THC | 66 | 3.04 | 1.71 |
| 13.4% THC | 62 | 2.99 | 2.05 |
| Placebo | 63 | 2.49 | 1.70 |
| 5.9% THC | 66 | 2.97 | 1.93 |
| 13.4% THC | 62 | 3.01 | 2.03 |
| Placebo | 63 | 2.15 | 1.89 |
| 5.9% THC | 66 | 3.04 | 2.16 |
| 13.4% THC | 62 | 2.65 | 1.72 |
| Placebo | 63 | 2.34 | 1.82 |
| 5.9% THC | 66 | 2.92 | 2.10 |
| 13.4% THC | 62 | 2.34 | 1.71 |
The number of times the participant touched the correct stimulus (circle) on the iPad, during modified Surrogate Reference Task (mSuRT). Range is from 8 to 32. A higher score is a better score.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | 30.7 | 1.80 |
| 5.9% THC | 66 | 29.9 | 2.76 |
| 13.4% THC | 62 | 30.6 | 1.42 |
| Placebo | 63 | 30.9 | 1.71 |
| 5.9% THC | 66 | 28.7 | 4.23 |
| 13.4% THC | 62 | 30.3 | 2.54 |
| Placebo | 63 | 30.3 | 2.16 |
| 5.9% THC | 66 | 29.6 | 2.56 |
| 13.4% THC | 62 | 30.4 | 1.69 |
| Placebo | 63 | 30.4 | 2.73 |
| 5.9% THC | 66 | 29.7 | 2.61 |
| 13.4% THC | 62 | 30.7 | 1.40 |
| Placebo | 63 | 31.0 | 1.44 |
| 5.9% THC | 66 | 30.3 | 2.65 |
| 13.4% THC | 62 | 31.1 | 1.05 |
Coherence is the correlation (0 to 1) between the participant and the lead car (which speeds up and slows down), representing the participant's ability to accurately speed up and slow down similarly to the lead car. Range of scores is from .01 to .97. A higher score is a better score.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | .76 | .19 |
| 5.9% THC | 66 | .73 | .18 |
| 13.4% THC | 62 | .76 | .15 |
| Placebo | 63 | .79 | .13 |
| 5.9% THC | 66 | .66 | .20 |
| 13.4% THC | 62 | .71 | .17 |
| Placebo | 63 | .77 | .16 |
| 5.9% THC | 66 | .65 | .23 |
| 13.4% THC | 62 | .68 | .19 |
| Placebo | 63 | .80 | .15 |
| 5.9% THC | 66 | .74 | .18 |
| 13.4% THC | 62 | .74 | .17 |
| Placebo | 63 | .75 | .16 |
| 5.9% THC | 66 | .74 | .18 |
| 13.4% THC | 62 | .71 | .17 |
Time delay (in seconds) in responding to changes in the lead car's speed. Range is from -5.8 to 6.0. A higher score indicates a worse score.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | 2.92 | 1.15 |
| 5.9% THC | 66 | 3.32 | 1.23 |
| 13.4% THC | 62 | 3.58 | 1.24 |
| Placebo | 63 | 2.86 | 1.05 |
| 5.9% THC | 66 | 3.44 | 1.15 |
| 13.4% THC | 62 | 3.55 | 1.06 |
| Placebo | 63 | 2.80 | .99 |
| 5.9% THC | 66 | 3.25 | 1.28 |
| 13.4% THC | 62 | 3.49 | 1.04 |
| Placebo | 63 | 2.61 | 1.04 |
| 5.9% THC | 66 | 2.83 | 1.05 |
| 13.4% THC | 62 | 3.23 | 1.18 |
| Placebo | 63 | 2.93 | 1.05 |
| 5.9% THC | 66 | 3.00 | 1.10 |
| 13.4% THC | 62 | 3.50 | 1.17 |
The outcome is distance from the lead car (in virtual feet) during the Car Following Task
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | 153 | 41 |
| 5.9% THC | 66 | 156 | 41 |
| 13.4% THC | 62 | 163 | 35 |
| Placebo | 63 | 143 | 36 |
| 5.9% THC | 66 | 165 | 39 |
| 13.4% THC | 62 | 164 | 39 |
| Placebo | 63 | 144 | 34 |
| 5.9% THC | 66 | 160 | 38 |
| 13.4% THC | 62 | 165 | 36 |
| Placebo | 63 | 129 | 33 |
| 5.9% THC | 66 | 137 | 37 |
| 13.4% THC | 62 | 150 | 34 |
| Placebo | 63 | 138 | 34 |
| 5.9% THC | 66 | 136 | 37 |
| 13.4% THC | 62 | 151 | 36 |
The participant follows a moving target (square) with her/his finger, and switches to following a new stimulus when it appears in the corner of the screen. Each participant was classified as to whether he/she missed any of these switches during the trial. The outcome is the proportion of participants within each group who missed at least one switch. The range is from 0 to 1. Higher indicates a worse score.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | 0.095 | 0.039 to 0.202 |
| 5.9% THC | 66 | 0.145 | 0.073 to 0.263 |
| 13.4% THC | 62 | 0.167 | 0.087 to 0.290 |
| Placebo | 63 | 0.095 | 0.039 to 0.202 |
| 5.9% THC | 66 | 0.194 | 0.108 to 0.317 |
| 13.4% THC | 62 | 0.183 | 0.099 to 0.309 |
| Placebo | 63 | 0.175 | 0.095 to 0.295 |
| 5.9% THC | 66 | 0.161 | 0.084 to 0.281 |
| 13.4% THC | 62 | 0.233 | 0.138 to 0.363 |
| Placebo | 63 | 0.191 | 0.106 to 0.313 |
| 5.9% THC | 66 | 0.177 | 0.096 to 0.299 |
| 13.4% THC | 62 | 0.167 | 0.087 to 0.290 |
| Placebo | 63 | 0.095 | 0.039 to 0.202 |
| 5.9% THC | 66 | 0.129 | 0.061 to 0.244 |
| 13.4% THC | 62 | 0.183 | 0.099 to 0.309 |
The participant is to rotate the iPad in order to keep a round object in the center, between two lines (lanes). This measure is the standard deviation of the position of the round object during the task (in essence, how much "swerving" there is within the lane). The range is from 8.2 to 189.4. A higher score indicates worse performance.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | 26.9 | 9.53 |
| 5.9% THC | 66 | 30.9 | 23.7 |
| 13.4% THC | 62 | 27.2 | 9.67 |
| Placebo | 63 | 28.7 | 13.4 |
| 5.9% THC | 66 | 30.9 | 15.7 |
| 13.4% THC | 62 | 32.1 | 21.7 |
| Placebo | 63 | 28.4 | 10.3 |
| 5.9% THC | 66 | 27.6 | 10.2 |
| 13.4% THC | 62 | 27.4 | 10.4 |
| Placebo | 63 | 28.1 | 13.3 |
| 5.9% THC | 66 | 29.9 | 15.5 |
| 13.4% THC | 62 | 28.6 | 14.8 |
| Placebo | 63 | 26.4 | 10.8 |
| 5.9% THC | 66 | 25.4 | 8.39 |
| 13.4% THC | 62 | 25.3 | 13.8 |
Assessment of short-term memory for abstract figures. The participant is to memorize abstract figures and their locations on a 3 x 3 grid. After initial viewing (10 seconds), the figures go away for either 4, 12, or 24 seconds. The participant is then to identify which figures were in the initial viewing (from a list at the bottom of the screen), and place them at the correct location. This is the number of correctly identified figures. The range is from 0 to 12. A higher score indicates better performance.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | 9.9 | 2.3 |
| 5.9% THC | 66 | 9.7 | 2.7 |
| 13.4% THC | 62 | 10.1 | 2.2 |
| Placebo | 63 | 9.1 | 2.8 |
| 5.9% THC | 66 | 8.4 | 2.6 |
| 13.4% THC | 62 | 9.3 | 2.7 |
| Placebo | 63 | 8.9 | 3.1 |
| 5.9% THC | 66 | 8.7 | 2.6 |
| 13.4% THC | 62 | 8.9 | 2.7 |
| Placebo | 63 | 8.5 | 3.0 |
| 5.9% THC | 66 | 8.3 | 2.9 |
| 13.4% THC | 62 | 8.8 | 2.5 |
| Placebo | 63 | 9.3 | 2.9 |
| 5.9% THC | 66 | 8.5 | 3.0 |
| 13.4% THC | 62 | 9.5 | 3.0 |
The participant is to estimate the amount of time that has passed while performing a secondary task. This outcome is the ratio of 1) the estimated time that has passed (seconds), divided by 2) the actual amount of time that has passed. The range is from 0.204 to 1.89. A higher score indicates a better performance.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | 0.75 | 0.19 |
| 5.9% THC | 66 | 0.83 | 0.30 |
| 13.4% THC | 62 | 0.77 | 0.22 |
| Placebo | 63 | 0.79 | 0.21 |
| 5.9% THC | 66 | 0.89 | 0.30 |
| 13.4% THC | 62 | 0.85 | 0.24 |
| Placebo | 63 | 0.83 | 0.20 |
| 5.9% THC | 66 | 0.96 | 0.30 |
| 13.4% THC | 62 | 0.87 | 0.27 |
| Placebo | 63 | 0.85 | 0.23 |
| 5.9% THC | 66 | 0.93 | 0.23 |
| 13.4% THC | 62 | 0.86 | 0.21 |
| Placebo | 63 | 0.83 | 0.20 |
| 5.9% THC | 66 | 0.89 | 0.28 |
| 13.4% THC | 62 | 0.85 | 0.21 |
While standing and keeping their feet still, this is a measure of the participant's "sway", which is the total distance that the participant's body moved (in meters) from his/her initial vertical position. This was measured using an accelerometer placed on the participant's back. The range of scores is from .222 to 1.661. A higher score indicates worse performance.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | 0.358 | 0.058 |
| 5.9% THC | 66 | 0.360 | 0.067 |
| 13.4% THC | 62 | 0.356 | 0.058 |
| Placebo | 63 | 0.342 | 0.054 |
| 5.9% THC | 66 | 0.376 | 0.090 |
| 13.4% THC | 62 | 0.363 | 0.129 |
| Placebo | 63 | 0.351 | 0.053 |
| 5.9% THC | 66 | 0.394 | 0.161 |
| 13.4% THC | 62 | 0.414 | 0.254 |
| Placebo | 63 | 0.354 | 0.058 |
| 5.9% THC | 66 | 0.386 | 0.131 |
| 13.4% THC | 62 | 0.377 | 0.133 |
| Placebo | 63 | 0.368 | 0.059 |
| 5.9% THC | 66 | 0.371 | 0.054 |
| 13.4% THC | 62 | 0.365 | 0.072 |
Spearman's correlation between THC concentrations in whole blood and oral fluid. Higher scores are better.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | 0.217 | -0.034 to 0.443 |
| 5.9% THC | 66 | 0.414 | 0.190 to 0.598 |
| 13.4% THC | 62 | 0.249 | -0.003 to 0.471 |
Spearman's correlation between THC concentrations in whole blood and breath
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Placebo | 63 | 0.134 | -0.120 to 0.371 |
| 5.9% THC | 66 | -0.258 | -0.472 to -0.015 |
| 13.4% THC | 62 | -0.176 | -0.410 to 0.079 |
| Milestone | Placebo Cannabis | Cannabis With 5.9% THC | Cannabis With 13.4% THC |
|---|---|---|---|
| STARTED | 65 | 70 | 64 |
| COMPLETED | 63 | 66 | 62 |
| NOT COMPLETED | 2 | 4 | 2 |
| Event | System | Groups: affected / at risk |
|---|---|---|
| Anxiety | Psychiatric disorders | Placebo Cannabis: 0 / 65 · Cannabis With 5.9% THC: 2 / 70 · Cannabis With 13.4% THC: 0 / 64 |
| Dizziness | Nervous system disorders | Placebo Cannabis: 0 / 65 · Cannabis With 5.9% THC: 3 / 70 · Cannabis With 13.4% THC: 3 / 64 |
| Nausea | Gastrointestinal disorders | Placebo Cannabis: 0 / 65 · Cannabis With 5.9% THC: 2 / 70 · Cannabis With 13.4% THC: 1 / 64 |
| Sweats | Nervous system disorders | Placebo Cannabis: 0 / 65 · Cannabis With 5.9% THC: 2 / 70 · Cannabis With 13.4% THC: 0 / 64 |
| Blood Pressure Decreased | Vascular disorders | Placebo Cannabis: 0 / 65 · Cannabis With 5.9% THC: 3 / 70 · Cannabis With 13.4% THC: 1 / 64 |
| Blood Pressure Increased | Vascular disorders | Placebo Cannabis: 0 / 65 · Cannabis With 5.9% THC: 2 / 70 · Cannabis With 13.4% THC: 0 / 64 |
| Heart Rate Abnormal | Cardiac disorders | Placebo Cannabis: 0 / 65 · Cannabis With 5.9% THC: 12 / 70 · Cannabis With 13.4% THC: 1 / 64 |
| Cervicalgia | General disorders | Placebo Cannabis: 0 / 65 · Cannabis With 5.9% THC: 1 / 70 · Cannabis With 13.4% THC: 0 / 64 |
| Fainting | Vascular disorders | Placebo Cannabis: 0 / 65 · Cannabis With 5.9% THC: 1 / 70 · Cannabis With 13.4% THC: 0 / 64 |
| Cough | Respiratory, thoracic and mediastinal disorders | Placebo Cannabis: 0 / 65 · Cannabis With 5.9% THC: 0 / 70 · Cannabis With 13.4% THC: 1 / 64 |
| Discomfort in arm | Injury, poisoning and procedural complications | Placebo Cannabis: 1 / 65 · Cannabis With 5.9% THC: 1 / 70 · Cannabis With 13.4% THC: 0 / 64 |
| Swollen arm | Injury, poisoning and procedural complications | Placebo Cannabis: 0 / 65 · Cannabis With 5.9% THC: 0 / 70 · Cannabis With 13.4% THC: 1 / 64 |
Eligibility
primary outcomes
Time frame: Participants are assessed pre-smoking, and then approximately 30m, 1h 30m, 3h 30m and 4h 30m post-smoking
The Composite Drive Score (CDS) is a z-score comprised of key variables from the simulator tasks (SDLP, speed deviation, and task accuracy during the modified Surrogate Reference Task (mSuRT); coherence from the car following task). This outcome reflects the change in CDS from the pre-smoking assessment, at each timepoint. The z-score indicates the number of standard deviations away from the mean from the baseline performance for the entire group (n = 191). A Z-score of 0 is equal to the mean of a reference population (in this case the pre-smoking performance for the entire group). Higher z-scores at each timepoint indicate worse performance (variables that went in the opposite direction were reflected in order to have all variables have the same direction). When examining the change in Composite Drive Score (this outcome variable), a higher score indicates a decline in performance (e.g., Time 2 minus Time 1).
secondary outcomes
Time frame: Participants are assessed pre-smoking, and then approximately 30m, 1h 30m, 3h 30m and 4h 30m post-smoking
This measures the standard deviation of lateral (lane) position, or the degree to which the participant "swerves" within the road lane on the driving simulation during the modified Surrogate Reference Task (mSuRT). The range is from .39 to 3.33. A higher score indicates worse performance.
Time frame: Participants are assessed pre-smoking, and then approximately 30m, 1h 30m, 3h 30m and 4h 30m post-smoking
The variability in speed during the modified Surrogate Reference Test (mSuRT). The speed is in miles per hour. Range is from .17 to 12.85. A higher score indicates worse performance.
Time frame: Participants are assessed pre-smoking, and then approximately 30m, 1h 30m, 3h 30m and 4h 30m post-smoking
The number of times the participant touched the correct stimulus (circle) on the iPad, during modified Surrogate Reference Task (mSuRT). Range is from 8 to 32. A higher score is a better score.
Time frame: Participants are assessed pre-smoking, and then approximately 30m, 1h 30m, 3h 30m and 4h 30m post-smoking
Coherence is the correlation (0 to 1) between the participant and the lead car (which speeds up and slows down), representing the participant's ability to accurately speed up and slow down similarly to the lead car. Range of scores is from .01 to .97. A higher score is a better score.
Time frame: Participants are assessed pre-smoking, and then approximately 30m, 1h 30m, 3h 30m and 4h 30m post-smoking
Time delay (in seconds) in responding to changes in the lead car's speed. Range is from -5.8 to 6.0. A higher score indicates a worse score.
Time frame: Participants are assessed pre-smoking, and then approximately 30m, 1h 30m, 3h 30m and 4h 30m post-smoking
The outcome is distance from the lead car (in virtual feet) during the Car Following Task
Time frame: Participants assessed pre-smoking and 1 hour, 2 hours, 4 hours, and 5 hours after smoking
The participant follows a moving target (square) with her/his finger, and switches to following a new stimulus when it appears in the corner of the screen. Each participant was classified as to whether he/she missed any of these switches during the trial. The outcome is the proportion of participants within each group who missed at least one switch. The range is from 0 to 1. Higher indicates a worse score.
Time frame: Participants assessed pre-smoking and 1 hour, 2 hours, 4 hours, and 5 hours after smoking
The participant is to rotate the iPad in order to keep a round object in the center, between two lines (lanes). This measure is the standard deviation of the position of the round object during the task (in essence, how much "swerving" there is within the lane). The range is from 8.2 to 189.4. A higher score indicates worse performance.
Time frame: Participants assessed pre-smoking and 1 hour, 2 hours, 4 hours, and 5 hours after smoking
Assessment of short-term memory for abstract figures. The participant is to memorize abstract figures and their locations on a 3 x 3 grid. After initial viewing (10 seconds), the figures go away for either 4, 12, or 24 seconds. The participant is then to identify which figures were in the initial viewing (from a list at the bottom of the screen), and place them at the correct location. This is the number of correctly identified figures. The range is from 0 to 12. A higher score indicates better performance.
Time frame: Participants assessed pre-smoking and 1 hour, 2 hours, 4 hours, and 5 hours after smoking
The participant is to estimate the amount of time that has passed while performing a secondary task. This outcome is the ratio of 1) the estimated time that has passed (seconds), divided by 2) the actual amount of time that has passed. The range is from 0.204 to 1.89. A higher score indicates a better performance.
Time frame: Participants assessed pre-smoking and 1 hour, 2 hours, 4 hours, and 5 hours after smoking
While standing and keeping their feet still, this is a measure of the participant's "sway", which is the total distance that the participant's body moved (in meters) from his/her initial vertical position. This was measured using an accelerometer placed on the participant's back. The range of scores is from .222 to 1.661. A higher score indicates worse performance.
Time frame: Approximately 15 minutes post-smoking
Spearman's correlation between THC concentrations in whole blood and oral fluid. Higher scores are better.
Time frame: Approximately 15 minutes post-smoking
Spearman's correlation between THC concentrations in whole blood and breath
Publications
| Numbness in arm | Injury, poisoning and procedural complications | Placebo Cannabis: 1 / 65 · Cannabis With 5.9% THC: 0 / 70 · Cannabis With 13.4% THC: 0 / 64 |
| Fever | General disorders | Placebo Cannabis: 0 / 65 · Cannabis With 5.9% THC: 1 / 70 · Cannabis With 13.4% THC: 0 / 64 |